Ethylbiscoum acetate
Structural formula | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | ||||||||||||||||||||||
Non-proprietary name | Ethylbiscoum acetate | |||||||||||||||||||||
other names |
|
|||||||||||||||||||||
Molecular formula | C 22 H 16 O 8 | |||||||||||||||||||||
Brief description |
bimorph crystals |
|||||||||||||||||||||
External identifiers / databases | ||||||||||||||||||||||
|
||||||||||||||||||||||
Drug information | ||||||||||||||||||||||
ATC code | ||||||||||||||||||||||
Drug class | ||||||||||||||||||||||
Mechanism of action |
Vitamin K antagonist |
|||||||||||||||||||||
properties | ||||||||||||||||||||||
Molar mass | 408.35 g · mol -1 | |||||||||||||||||||||
Physical state |
firmly |
|||||||||||||||||||||
Melting point |
177-182 ° C and 154-157 ° C, respectively |
|||||||||||||||||||||
pK s value |
3.1 |
|||||||||||||||||||||
safety instructions | ||||||||||||||||||||||
|
||||||||||||||||||||||
Toxicological data | ||||||||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Ethylbiscoumacetat is the international non-proprietary name of bis (4-hydroxy-2-oxo-2 H -chromen-3-yl) -acetic acid ethyl ester, a chemical compound from the group of 4-hydroxycoumarins with an anticoagulant effect. It was marketed under the trade name Tromexan by the Swiss pharmaceutical company JR Geigy in the 1950s .
chemistry
Ethylbiscoumacetat crystallizes in two different forms ( bimorphism ), which differ in their melting point.
Clinical information
Application areas (indications)
It is used for controlled anticoagulation, for example in treatment or as a precaution against a tendency to thrombotic diseases.
Adverse effects (side effects)
As a possible side effect, ethylbiscoum acetate can relieve bleeding and hematomas due to its inhibition of coagulation , but fever, nausea and diarrhea or rashes of the skin can also occur .
Pharmacological properties
Mechanism of action (pharmacodynamics)
It exerts its protein anticoagulation by inhibiting the enzymatic reduction of Vitamin K . It works just like other coumarin variants , such as acenocumarol , dicoumarol or warfarin .
Absorption and distribution in the body (pharmacokinetics)
Ethylbiscoum acetate is ingested orally and is ultimately largely absorbed by the body. In the bloodstream it binds and changes 95% of the proteins of the blood plasma , and finally it is broken down again in the liver.
literature
- Article in the pharmaceutical newspaper
- Hager's Handbook of Pharmaceutical Practice, Volume 7, p. 125 ( limited preview in Google book search).
Individual evidence
- ↑ a b c d e f Entry on Ethylbiscoumacetat. In: Römpp Online . Georg Thieme Verlag, accessed on March 6, 2011.
- ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.